Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Monoclonal antibodies can locate cancer cells and either kill
them or deliver cancer-killing substances to them without harming normal cells. It is not yet
known if combining combination chemotherapy with monoclonal antibody therapy will kill more
cancer cells.
PURPOSE: Randomized phase III trial to determine the effectiveness of combination
chemotherapy with or without gemtuzumab ozogamicin in treating patients who have acute
myeloid leukemia.
Phase:
Phase 3
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC